The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs
Open accessAbstract
Drugs with low water solubility are predisposed to poor and variable oral bioavailability and, therefore, to variability in clinical response, that might be overcome through an appropriate formulation of the drug. Polymorphs (anhydrous and solvate/hydrate forms) may resolve these bioavailability problems, but they can be a challenge to ensure physicochemical stability for the entire shelf life of the drug product. Since clinical failures of polymorph drugs have not been uncommon, and some of them have been entirely unexpected, the Food and Drug Administration (FDA) and the International Conference on Harmonization (ICH) has required preliminary and exhaustive screening studies to identify and characterize all the polymorph crystal forms for each drug. In the past, the polymorphism of many drugs was detected fortuitously or through manual time consuming methods; today, drug crystal engineering, in particular, combinatorial chemistry and high-throughput screening, makes it possible to easily and exhaustively identify stable polymorphic and/or hydrate/dehydrate forms of poorly soluble drugs, in order to overcome bioavailability related problems or clinical failures. This review describes the concepts involved, provides examples of drugs characterized by poor solubility for which polymorphism has proven important, outlines the state-of-the-art technologies and discusses the pertinent regulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Improving drug solubility for oral delivery using solid dispersions
Leuner, C. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00076-x · Cited by 2,574
Photodimerization in the solid state
Schmidt, G. M. J. (1971) · Pure and Applied Chemistry · doi:10.1351/pac197127040647 · Cited by 2,095
Drug Solubility: Importance and Enhancement Techniques
Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012) · ISRN Pharmaceutics · doi:10.5402/2012/195727 · Cited by 2,004
The Theory and Practice of Industrial Pharmacy
Lachman, L., Lieberman, H. A., & Kanig, J. L. (1970) · Virtual Defense Library (Ministerio de Defensa) · Cited by 1,838
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates
Blagden, N., de Matas, M., Gavan, P. T., & York, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.011 · Cited by 1,448
Salt formation to improve drug solubility
Serajuddin, A. T. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.010 · Cited by 1,425
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Hancock, B. C., & Parks, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007516718048 · Cited by 1,358
Cyclodextrins in drug delivery: An updated review
Challa, R., Ahuja, A., Ali, J., & Khar, R. K. (2005) · AAPS PharmSciTech · doi:10.1208/pt060243 · Cited by 1,215
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
Ritonavir: An Extraordinary Example of Conformational Polymorphism
Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., & Morris, J. (2001) · Pharmaceutical Research · doi:10.1023/a:1011052932607 · Cited by 1,071
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J. T., Kim, H., Cho, J. M., Yun, G., & Lee, J. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.05.005 · Cited by 998
Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development
Chemburkar, S. R., Bauer, J., Deming, K., Spiwek, H., Patel, K., Morris, J., Henry, R., Spanton, S., Dziki, W., Porter, W., et al. (2000) · Organic Process Research & Development · doi:10.1021/op000023y · Cited by 687
Vippagunta, S. R., Brittain, H. G., & Grant, D. J. W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00097-7 · Cited by 670
Nanonization strategies for poorly water-soluble drugs
Chen, H., Khemtong, C., Yang, X., Chang, X., & Gao, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.009 · Cited by 642
Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0600182 · Cited by 606
Desiraju, G. R. (2001) · Nature · doi:10.1038/35086640 · Cited by 602
Drug polymorphism and dosage form design: a practical perspective
Singhal, D. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.008 · Cited by 596
Crystal structures of drugs: advances in determination, prediction and engineering
Datta, S., & Grant, D. J. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1280 · Cited by 583
Trends in Solubility of Polymorphs
Pudipeddi, M., & Serajuddin, A. T. M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20302 · Cited by 505
Khankari, R. K., & Grant, D. J. W. (1995) · Thermochimica Acta · doi:10.1016/0040-6031(94)01952-d · Cited by 485
Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations
Byrn, S. R., Pfeiffer, R. R., Ganey, M. E., Hoiberg, C. P., & Poochikian, G. (1995) · Pharmaceutical Research · doi:10.1023/a:1016241927429 · Cited by 476
Zhang, G. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.009 · Cited by 462
Impact of solid state properties on developability assessment of drug candidates
Huang, L. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.007 · Cited by 438
Gao, L., Zhang, D., & Chen, M. (2008) · Journal of Nanoparticle Research · doi:10.1007/s11051-008-9357-4 · Cited by 420
Dissolution Behavior of Crystalline Solvated and Nonsolvated Forms of Some Pharmaceuticals
Shefter, E., & Higuchi, T. (1963) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600520815 · Cited by 373
Benet, L. Z. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23359 · Cited by 342
Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate
Aguiar, A. J., Krc, J., Kinkel, A. W., & Samyn, J. C. (1967) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600560712 · Cited by 307
The Use of Polymer Heteronuclei for Crystalline Polymorph Selection
Lang, M., Grzesiak, A. L., & Matzger, A. J. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0286526 · Cited by 223
Ku, M. S., & Dulin, W. (2012) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2010.535826 · Cited by 172
Dissolution Behavior of Polymorphs of Chloramphenicol Palmitate and Mefenamic Acid
Aguiar, A. J., & Zelmer, J. E. (1969) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600580817 · Cited by 170
Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement
Murdande, S. B., Pikal, M. J., Shanker, R. M., & Bogner, R. H. (2010) · Pharmaceutical Development and Technology · doi:10.3109/10837451003774377 · Cited by 160
Rifaximin: In vitro and in vivo Antibacterial Activity – A Review
Jiang, Z. D., & DuPont, H. L. (2005) · Chemotherapy · doi:10.1159/000081991 · Cited by 158
The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures
Meyer, M. C., Straughn, A. B., Jarvi, E. J., Wood, G. C., Pelsor, F. R., & Shah, V. P. (1992) · Pharmaceutical Research · doi:10.1023/a:1015872626887 · Cited by 157
Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders
Adachi, J. A., & DuPont, H. L. (2006) · Clinical Infectious Diseases · doi:10.1086/499950 · Cited by 146
Solid State Characterization of Commercial Crystalline and Amorphous Atorvastatin Calcium Samples
Shete, G., Puri, V., Kumar, L., & Bansal, A. K. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9419-7 · Cited by 122
Polymorphism in generic drug product development
Snider, D. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.010 · Cited by 119
High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate
Kojima, T., Tsutsumi, S., Yamamoto, K., Ikeda, Y., & Moriwaki, T. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.055 · Cited by 107
Prediction of the crystal structures of axitinib, a polymorphic pharmaceutical molecule
Vasileiadis, M., Pantelides, C. C., & Adjiman, C. S. (2014) · Chemical Engineering Science · doi:10.1016/j.ces.2014.08.058 · Cited by 80
Scarpignato, C., Blandizzi, C., & Viscomi, G. C. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s72572 · Cited by 46
Chadha, R., Kuhad, A., Arora, P., & Kishor, S. (2012) · Chemistry Central Journal · doi:10.1186/1752-153x-6-114 · Cited by 36
Dissolution Enhancement of Poorly Soluble Drugs by Using Complexation Technique - A Review
Saravana Kumar, K., Sushma, M., & Prasanna Raju, Y. (2013) · Cited by 31
Polymorphic Crystal Forms and Cocrystals in Drug Delivery (Crystal Engineering)
Shan, N., & Zaworotko, M. J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc156 · Cited by 22
Use of rabbits for absorption studies on polymorphs of chloramphenicol palmitate.
MAEDA, T., Takenaka, H., Yamahira, Y., & NOGUCHI, T. (1980) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.28.431 · Cited by 16
Cited by
Dima, C., Assadpour, E., Dima, S., & Jafari, S. M. (2020) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12623 · Cited by 304
Nanonization techniques to overcome poor water-solubility with drugs
Da Silva, F. L. O., Marques, M. B. D. F., Kato, K. C., & Carneiro, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1750591 · Cited by 136
Metadata
- Authors
- Censi, R., & Di Martino, P.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-10-15
- Volume
- 20
- Issue
- 10
- Pages
- 18759-18776
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2142720002
- Cited by
- 512
- References
- 48
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.